Office for Life Sciences

Add links
Source: Wikipedia, the free encyclopedia.

Office for Life Sciences
AbbreviationOLS
Formation2009
Legal statusGovernment unit
PurposeGovernment advisory for life sciences policy
Region served
United Kingdom
Director
Roz Campion
AffiliationsDepartment for Science, Innovation and Technology Department of Health and Social Care
Websitewww.gov.uk/government/organisations/office-for-life-sciences Edit this at Wikidata

The Office for Life Sciences (OLS) is part of the British government. The organisation supports the delivery of the UK Government's life sciences and innovation policy by connecting decision making across government.[1] Informed by productive engagement with industry, the OLS promotes research, innovation, and technology within government for the improvement of healthcare.[2][3]

The office sits across the

Science, Innovation and Technology Select Committee, and the Health and Social Care Select Committee.

History

The Office for Life Sciences was created in 2009 following an announcement by

Lord Drayson as Minister of State for Science and Innovation.[6]

Leadership

The Office for Life Sciences is a joint-government office of the Department for Science, Innovation and Technology and the Department of Health and Social Care, and is answerable to government ministers.

The OLS is headed up by civil servants, with the leadership as follows:

Position Name Tenure
Director Kristen McLeod[7] October 2017 - November 2021
Rosalind Campion November 2021 - present

Strategy

Life Sciences Blueprint (2009–2010)

The Life Sciences Blueprint, published in July 2009, set out a vision for UK life sciences policy which the OLS was tasked with supporting. The blueprint focused on:[8]

  • Strengthening the NHS champion for innovation
  • Building a more integrated life sciences strategy
  • Ensuring access to finance and stimulating investment
  • Marketing the UK's life sciences industry internationally.

Strategy for UK Life Sciences (2011–2017)

The Strategy for UK Life Sciences was published in December 2011 and led by the

Conservative-Liberal Democrat coalition government, which expanded upon the work of the previous Labour administration in building the UK's life sciences clout.[10] The strategy outlined an agenda for regulatory and medicines access reform to boost UK attractiveness and to deliver greater innovation within the NHS and the wider healthcare system.[9][10][11]

Life Sciences Industrial Strategy (2017–2021)

The UK's Industrial Strategy

UK's scientific and research base.[15]

The Life Sciences Industrial Strategy was accompanied by two negotiated 'sector deals', a type of bespoke arrangement between government and industry,

genomic sequencing capabilities.[13] In January 2020, an update to the strategy was published by the UK Government which examined the progress to date in achieving the 2017 vision.[16]

Life Sciences Vision (2021–present)

In March 2021, it was announced that the UK Government would introduce a new plan for growth to replace the Industrial Strategy.

Business Secretary Kwasi Kwarteng set out the government's vision for the Plan for Growth[18] which would take advantage of COVID-19 recovery planning to deliver the ambitions of the 2019 Conservative Party manifesto. The plan is the legacy of Downing Street advisor Dominic Cummings which seeks to place technology and innovation at the heart of the UK’s economic future.[17] The Plan for Growth continues elements of the Industrial Strategy, including the Life Science Sector Deals, and policy specific proposals would be made within 12 months of its publication.[18]

Following the publication of the Plan for Growth, the UK Government published the Life Sciences Vision in July 2021 which set out a policy specific framework for the government's approach to life sciences policy.[19] At the centre of the framework is the vision to make the UK the globally leading location for life sciences within a decade, by 2031.[20]

It sets out three core collaborative ambitions:[19]

  • Build on the UK’s world class science and research capabilities – making the UK the best place in the world to trial and test products at scale, underpinned by an ever improving genomic and health data infrastructure
  • Make the NHS the country’s most powerful driver of innovation – through the development, testing and adoption of new technologies at a population-scale, using new technology to get diagnosis and treatment right first time, and building genuine trust between the NHS and the sector about what can be achieved by working closely together
  • Create an outstanding business environment for Life Science companies – in which incentives and structures are aligned to support company growth, innovation and investment – underpinned by a world class regulatory environment and bringing to bear the full financial firepower of the City of London to support companies to grow

It sets out seven healthcare missions (eight combined with the government's drug strategy) for the sector to ecourage innovation and address unmet clinical need:[19][20]

  1. Improving translational capabilities in neurodegeneration and dementia
  2. Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines
  3. Sustaining the UK position in novel vaccine discovery development and manufacturing
  4. Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity
  5. Reducing mortality and morbidity from respiratory disease in the UK and globally
  6. Addressing the underlying biology of ageing
  7. Increasing the understanding of mental health conditions, including work to redefine diseases and develop translational tools to address them.

The Life Sciences Vision sits within and underneath the overarching cross-governmental and cross-sector Plan for Growth.[19]

Work of the OLS

Life sciences indicators

Since 2015, the Office for Life Sciences has published data annually which assesses UK life science sector performance against international standards, practices, and trends.[21] The indicators cover the research environment, domestic market, production environment, international collaboration, investment environment, and access to skilled labour.[21]

The data is routinely used by policy makers to track sector performance. In July 2023, the UK's primary pharmaceutical representative body, the Association of the British Pharmaceutical Industry (ABPI), responded to a publication of the indicators and assessed that inward life sciences foreign direct investment (FDI) had fallen by 47% in 2022 compared to 2021, falling to £1 billion from £1.9 billion.[22]

References

  1. ^ a b "Government creates Office for Life Sciences". PMLive. 6 April 2009. Retrieved 16 April 2021.
  2. ^ "Our place in the UK research landscape". NIHR. Retrieved 16 April 2021.
  3. ^ "Office for Life Sciences: About us". GOV.UK. Retrieved 16 April 2021.
  4. ^ "Latest update from the Office for Life Sciences (OLS)". Medilink West Midlands. 7 February 2020. Retrieved 19 April 2021.
  5. ^ Taylor, Lynne (7 April 2009). "UK's OLS "to make a real difference to pharma/biotech"". PharmaTimes. Retrieved 16 April 2021.
  6. ^ "Lord Drayson on new technology that could power devices for free". www.managementtoday.co.uk. Retrieved 16 April 2021.
  7. ^ "The Board | Genomics England". 2013-07-01. Retrieved 2021-04-21.
  8. ^ "Departmental Report 2009" (PDF). GOV.UK. Department for Innovation, Universities and Skills. Retrieved 16 April 2021.
  9. ^ a b "Strategy for UK Life Sciences" (PDF). Department for Business, Innovation and Skills. December 2011. Retrieved 17 April 2021.
  10. ^ a b Philippidis, Alex (2012-01-16). "U.K. Counts on New Strategy to Push Biopharma Startups Past "Valley of Death"". GEN – Genetic Engineering and Biotechnology News. Retrieved 2021-04-17.
  11. ^ "House of Commons Science and Technology Committee: Bridging the "valley of death": improving the commercialisation of research – Response by the Wellcome Trust" (PDF). Wellcome Trust. February 2012. Retrieved 17 April 2021.
  12. ^ "Life Sciences Industrial Strategy" (PDF). Office for Life Sciences. 30 August 2017. Retrieved 17 April 2021.
  13. ^ a b c "Research Briefing – Industrial strategy" (PDF). UK Parliament. House of Commons Library. 8 August 2019. Retrieved 17 April 2021.
  14. ^ "Read Theresa May's keynote speech to the Conservative conference in full". The Independent. 2016-10-05. Retrieved 2021-04-17.
  15. ^ a b "Life Sciences Industrial Strategy". www.abpi.org.uk. Retrieved 2021-04-17.
  16. ^ "Life sciences industrial strategy update". GOV.UK. Retrieved 2021-04-17.
  17. ^ a b "UK industrial strategy refresh ditched as ministers set out plan for growth". www.ft.com. Retrieved 18 April 2021.
  18. ^ a b "Letter from Chancellor Rishi Sunak and Business Secretary Kwasi Kwarteng to businesses on the government's Plan for Growth". GOV.UK. Retrieved 2021-04-18.
  19. ^ a b c d "Life Sciences Vision". GOV.UK. Retrieved 2023-12-10.
  20. ^ a b "Delivery of the life science vision healthcare missions" (PDF). NHS Accelerated Access Collaborative. NHS England. July 2022. Retrieved 10 December 2023.
  21. ^ a b "Life science sector data". GOV.UK. 2023-07-13. Retrieved 2023-12-10.
  22. ^ "UK life science inward investment in freefall". www.abpi.org.uk. 2023-12-07. Retrieved 2023-12-10.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Office_for_Life_Sciences&oldid=1211090077"